secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001437749-25-038079
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports positive Phase 1 results for WP1066 in pediatric malignant brain tumors
--------------------------------------------------------------------------------

- WP1066 showed no significant toxicity and determined maximum feasible dose in 10 children with high-grade glioma.
- Partial tumor response observed in a DIPG patient; anti-tumor immune responses demonstrated via STAT3 suppression.
- Results published in Journal of Clinical Investigation Insight; Phase 2 trial warranted based on findings.
- Compassionate use in 3 additional children with high-grade glioma also evaluated.
- Study funded by Peach Bowl LegACy Fund and CURE Childhood Cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925038079/0001437749-25-038079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925038079/mbrx20251216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer